CN1175810C - Composition containing calcium ascorbate and calcium L-threonate - Google Patents
Composition containing calcium ascorbate and calcium L-threonate Download PDFInfo
- Publication number
- CN1175810C CN1175810C CNB01136954XA CN01136954A CN1175810C CN 1175810 C CN1175810 C CN 1175810C CN B01136954X A CNB01136954X A CN B01136954XA CN 01136954 A CN01136954 A CN 01136954A CN 1175810 C CN1175810 C CN 1175810C
- Authority
- CN
- China
- Prior art keywords
- calcium
- present
- vitamin
- compositions
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a medical composition containing calcium vitamin C and calcium L-threonate. Animal experiments prove that the combined use of the calcium vitamin C and the calcium L-threonate can promote the absorption and the utilization of vitamins C and calcium and can stengthen immunity, etc. The composition of the present invention can be used for supplementing the vitamins C and the calcium, treating diseases caused by the deficiency of the vitamins C and the calcium, strengthening and regulating the immunity.
Description
Invention field
The present invention relates to a kind of compositions that contains calcium ascorbate and l threonic acid, said composition can be used for vitimin supplement C and calcium, the disease that treatment vitamin and/or calcium deficiency cause and be used for strengthening and regulating immunity.
Background technology
Vitamin C is associated with hundreds of function of human body, and vitamin deficiency can cause multisystem disease, vitamin C deficiency as everyone knows.According to the study, vitamin has the removing interior free yl, antioxidation, and blood fat reducing, enhancing immunity prevents tired and mental disorder, improves effects such as learning and memory function, can reduce cancer morbidity, reduces cardiovascular diseases's M ﹠ M etc.Human body self can not synthetic vitamin C, need absorb from food, and normal diet often is not enough to satisfy the aggregate demand of human body to vitamin.
Calcium also is the human body trace elements necessary.Calcium participates in skeleton and forms, and cell information is transmitted, and hormone discharges, different physiological roles such as human internal environment's osmotic pressure balance.According to statistics, China most people, especially old people and child exist calcium deficiency, need to replenish in addition calcium.
Summary of the invention
The inventor finds through a large amount of experiments, calcium ascorbate and l threonic acid are used in combination, has unexpected synergism, can promote the absorption of vitamin and calcium simultaneously, increase the utilization of cell to vitamin C and calcium, l threonic acid can also delay the vitamin C time of staying in vivo.The present invention simultaneously replaces traditional vitamin C with calcium ascorbate, and it is non-acid, and pH=7 has avoided the gastrointestinal stimulation, and child preferably uses.The inventor finds that also the conjugate of the two has tangible enhancing and regulates the effect of laboratory animal immunity.
Therefore, an object of the present invention is to provide a kind of pharmaceutical composition that contains calcium ascorbate and l threonic acid.Compositions of the present invention can also contain pharmaceutically acceptable carrier, and other optional composition, as sweeting agent, coloring agent etc.
According to one embodiment of the invention, compositions of the present invention comprises:
The calcium ascorbate of 1-99.9wt%
The l threonic acid of 0.1-99wt%
Other composition of 0-98.9wt%.
In the embodiment of present invention further optimization, compositions of the present invention comprises:
The calcium ascorbate of 30-98.5wt%
The l threonic acid of 1-11wt%
Other composition of 0.5-59wt%.
In the also preferred embodiment of the present invention, compositions of the present invention comprises:
The calcium ascorbate of 40-70wt%
The l threonic acid of 2-6wt%
Other composition of 24-58wt%.
Wherein said other composition is selected from carrier, flavouring agent, sweeting agent, coloring agent etc., perhaps their conjugate.Carrier comprises those that use always in this area, for example diluent, excipient, stabilizing agent, thickening agent, suspending agent, emulsifying agent, buffer agent etc., can exemplify water, cellulose, starch, sucrose, magnesium stearate, PVP, lactose etc., compositions of the present invention can comprise one or more these carriers.
Compositions of the present invention can be made any dosage form that is suitable for using, for example capsule, oral liquid, tablet, slow releasing tablet, transfusion, injection etc.
Below in conjunction with embodiment the present invention is described, it should be noted that these embodiment are the preferred embodiments of the invention, do not constitute any limitation of the invention.
Specific embodiment
Embodiment 1 preparation capsule of the present invention
Calcium ascorbate 394 grams and l threonic acid 23.7 gram mix homogeneously add Pulvis Talci 4.22 grams again, and mix homogeneously divides to install in the capsule, and packing is made 1000 capsules.
The preparation of embodiment 2 oral liquids of the present invention
Calcium ascorbate 394 grams, l threonic acid 23.7 grams, sucrose 88.5 grams, citric acid 9.46 grams, aspartame 4.3 grams, potassium sorbate 0.18 gram adds water to 1000 milliliters, and heating for dissolving adds essence, stirs, and divides in the bottle that installs to sterilization, and packing gets final product.
The preparation of embodiment 3 tablets of the present invention
Calcium ascorbate 394 grams and l threonic acid 23.7 grams and pregelatinized Starch 200 gram mix homogeneously add 5%PVP (PVP30 gram) and 25% alcoholic solution again, fully mix, and soft material is granulated with 18 orders, and oven dry adds magnesium stearate 7 gram granulate, tabletting, packing.
The preparation of embodiment 4 slow releasing tablets of the present invention
Calcium ascorbate 394 grams and l threonic acid mix homogeneously add 5%PVP, 25% alcoholic solution mix homogeneously, and soft material is granulated with 18 orders, and oven dry adds HPMC, magnesium stearate granulate, tabletting, packing.
The preparation of embodiment 5 the present invention transfusion
Calcium ascorbate 394 grams and l threonic acid 23.7 grams add water and are settled to 1000 milliliters, and reheat dissolving, check, packing are gone in the bottle of sterilization, packing.
Embodiment 6
Calcium ascorbate 412 grams and l threonic acid 6.3 gram mix homogeneously add Pulvis Talci 4.67 grams again, and mix homogeneously divides to install in the capsule, and packing is made 1000 capsules.
Experiment one absorbs and utilizes and test
Experimental animal rat, 5 of 5 of separating tests groups and matched groups, test group according to 0.35g (vitamin C+l threonic acid)/kg body weight with oral liquid gastric infusion of the present invention, with matched group vitamin C 0.35g/kg body weight gastric infusion, after administration 20 minutes the time respectively vein get blood, the result shows that the mean concentration of test group vitamin C in blood is 23ug, and the mean concentration of matched group vitamin C in blood is 14ug.The urine of test experience rat found that test group average detected in urine is 2 times of matched group to the ascorbic time simultaneously.Show that compositions of the present invention helps ascorbic absorption and utilization.
Test the anti-vitamin C deficiency activity of two present compositions
ODS rat model (itself can not synthetic vitamin C) is divided into two groups, use the present composition (0.44mg/kg/day) and vitamin C (0.55mg/kg/day) administration 24 days respectively, the result shows that the rat group with the present composition has anti-vitamin C deficiency activity, and anti-vitamin C deficiency activity does not appear in the vitamin C group.Show under the help of l threonic acid the easier absorption of vitamin C.
Test the test of pesticide effectiveness of the immunoregulation effect of three pharmaceutical compositions of the present invention
1, test rating: spleen of mice and thymic weight; Antibody forming cell's (PFC) mensuration is with Je rne improvement slide method; Delayed allergy (DTH) is measured with the pedal swelling method; The detection of macrophage phagocytic function is measured with the carbon clearance method.Statistical method: with two groups of mean t checks.
2, laboratory animal: Kunming kind female mice, age in 6-8 week, 18-22 gram.Department Of Medicine, Peking University laboratory animal portion provides, and the quality certification number is: the moving word 01-3049 of doctor.
3, experimental design: animal is divided matched group, low dose group, middle dosage group and high dose group.Use capsule of the present invention, the dosage of above-mentioned three experimental grouies is respectively 0.1g/kg, 0.2g/kg and 0.4g/kg body weight.Be equivalent to 10,20,40 times of people's consumption every day respectively, the continuous irrigation stomach is 14 days altogether.
4, result
(1) thymic weight of middle and high dosage group mice and matched group relatively have tangible increase (table 1); Each is organized the spleen weight of mice and is not seen significant change.
(2) middle and high dosage group mice IgM-PFC number/full spleen and apparent in view increase (table 2) of matched group.
(3) delayed allergy (DTH) of dosage group mice relatively has obvious enhancing with matched group in, though high dose group and matched group relatively increase unknown significance difference (table 3) to some extent.
(4) middle and high dosage group mice carbon clearance rate (K) and clean up index (α) and matched group and relatively be significantly increased (table 4).
Table 1 present composition is to mouse immune organ weight's influence (X ± S)
Group n spleen phase counterweight thymus phase counterweight
Solvent control 12 5.53 ± 0.98 3.52 ± 0.55
Low dose group 12 5.54 ± 1.10 3.69 ± 1.04
Middle dosage group 12 5.82 ± 1.17 4.22 ± 0.59*
High dose group 11 5.20 ± 0.36 4.06 ± 0.76*
(mg)/body weight (g) in phase counterweight=internal organs
Compare * P＜0.05 with matched group
Table 2 present composition is to the influence of mice IgM-PFC/ spleen (X ± S)
The full spleen of group N IgM-PFC/
Solvent control 12 27.648 ± 1.60
Low dose group 12 25.703 ± 1.93
Middle dosage group 12 43.287 ± 1.49*
High dose group 11 57.906 ± 1.62**
Compare * P＜0.05, * * P＜0.01 with matched group
Table 3 present composition is to the influence of mouse DTH reaction (X ± S)
The group N foot sole of the foot increases thickness (mm)
Solvent control 12 0.49 ± 0.21
Low dose group 12 0.53 ± 0.24
Middle dosage group 12 0.67 ± 0.25*
High dose group 11 0.61 ± 0.28
Compare * P＜0.05 with matched group
Table 4 present composition is to the influence of mice carbon clearance (X ± S)
Group n K
Solvent control 11 0.0149 ± 0.0061 4.58 ± 0.80
Low dose group 11 0.0172 ± 0.0094 4.71 ± 0.71
Middle dosage group 11 0.0217 ± 0.0075* 5.25 ± 0.79*
High dose group 12 0.0192 ± 0.0049* 5.17 ± 0.45*
Compare * P＜0.05 with matched group
Its mouse oral gives after the present composition 14 days, and testing result shows that the present composition has tangible potentiation to humoral immune function (IgM-PFC) and the macrophage phagocytic function of mice; Pair cell immunologic function (DTH) also has certain potentiation simultaneously.
Claims (6)
1, a kind of compositions is characterised in that it comprises:
The calcium ascorbate of 30-98.5wt%
The l threonic acid of 1-11wt%
Optional carrier, coloring agent, flavouring agent, sweeting agent, perhaps other composition in their conjugate of being selected from.
2,, be characterised in that it comprises according to the compositions of claim 1:
The calcium ascorbate of 40-70wt%
The l threonic acid of 2-6wt%
24-58wt% is selected from carrier, coloring agent, flavouring agent, sweeting agent, perhaps other composition in their conjugate.
3, claim 1 or 2 the compositions application in the medicine of preparation vitimin supplement C and/or calcium.
4, claim 1 or 2 the compositions application in preparation antiscorbutic medicine.
5, claim 1 or 2 compositions are used for strengthening and regulating the application of the medicine of immunity in preparation.
6, claim 1 or 2 compositions is characterized in that calcium ascorbate and l threonic acid use with 394: 23.7 weight ratio.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB01136954XA CN1175810C (en) | 2001-12-26 | 2001-12-26 | Composition containing calcium ascorbate and calcium L-threonate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB01136954XA CN1175810C (en) | 2001-12-26 | 2001-12-26 | Composition containing calcium ascorbate and calcium L-threonate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1357326A CN1357326A (en) | 2002-07-10 |
| CN1175810C true CN1175810C (en) | 2004-11-17 |
Family
ID=4674034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB01136954XA Expired - Fee Related CN1175810C (en) | 2001-12-26 | 2001-12-26 | Composition containing calcium ascorbate and calcium L-threonate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1175810C (en) |
-
2001
- 2001-12-26 CN CNB01136954XA patent/CN1175810C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1357326A (en) | 2002-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101036515A (en) | Physical recovery healthy food and preparation process thereof | |
| CN101278928B (en) | Medicament composition containing levocarnitine or its derivatives and use thereof | |
| CN102357105B (en) | Combination with effect of enhancing immunity and application thereof | |
| CN101049323A (en) | Health protection medicine in use for treating chronic degenerative diseases, and producing method | |
| CN1175810C (en) | Composition containing calcium ascorbate and calcium L-threonate | |
| CN1179726C (en) | Application of naringin in preparing medicine for supporting treatment of SARS | |
| CN1663563A (en) | Compound troxerutin and piracetam formulation and application thereof | |
| CN1107501C (en) | Albendazole emulsion | |
| CN1935151A (en) | Weight-reducing medicine or health product | |
| CN1262270C (en) | Application of levocarnitine and its derivative in preventing and treating high altitude diseases | |
| CN1254261C (en) | Medicine for increasing organism immunological functioning and preparing method thereof | |
| CN1537541A (en) | Applicaton of montmorillonite inpreparing medicine | |
| CN1389265A (en) | Composite Chinese medicine with health care function | |
| CN106491664A (en) | A kind of Chinese medicine composition for treating pig virus diarrhoea | |
| CN1112012A (en) | Biological oral liquid | |
| CN1040063C (en) | Zinc gluconate for calming sathma and cough | |
| CN1689579A (en) | Application of burdock glycoside or its aglycon in preparation of medicine for treating diabetes or its complications | |
| CN1203865C (en) | Injection for enhancing immunity and its preparing method | |
| CN1440291A (en) | Pharmaceutical composition based on non-steroid anti-inflammatory agent | |
| CN1679611A (en) | Compound preparation of piracetam and its use | |
| CN1799410A (en) | Diet fiber composition with blood lipid-reducing blood sugar-decreasing functions and its production method | |
| CN1171594C (en) | Composition containing pearl powder and ascorbic acid | |
| CN100490824C (en) | Medicinal composition for treating blood vessel kind disease, its preparation process and its use | |
| CN107595829B (en) | A kind of composition for preventing and treating renal osteodystrophy | |
| CN1240389C (en) | Sulfony lated acetylglucosamine medicinal composition and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20041117 Termination date: 20100128 |